129 related articles for article (PubMed ID: 11069232)
1. Oral ganciclovir in children: pharmacokinetics, safety, tolerance, and antiviral effects. The Pediatric AIDS Clinical Trials Group.
Frenkel LM; Capparelli EV; Dankner WM; Xu J; Smith IL; Ballow A; Culnane M; Read JS; Thompson M; Mohan KM; Shaver A; Robinson CA; Stempien MJ; Burchett SK; Melvin AJ; Borkowsky W; Petru A; Kovacs A; Yogev R; Goldsmith J; McFarland EJ; Spector SA
J Infect Dis; 2000 Dec; 182(6):1616-24. PubMed ID: 11069232
[TBL] [Abstract][Full Text] [Related]
2. Response of asymptomatic cytomegalovirus viraemia to oral ganciclovir 3 g/day or 6 g/day in HIV-infected patients.
Grzywacz M; Deayton JR; Bowen EF; Wilson P; Emery VC; Johnson MA; Griffiths PD
J Med Virol; 1999 Nov; 59(3):323-8. PubMed ID: 10502264
[TBL] [Abstract][Full Text] [Related]
3. Oral ganciclovir in pediatric transplant recipients: a pharmacokinetic study.
Pescovitz MD; Brook B; Jindal RM; Leapman SB; Milgrom ML; Filo RS
Clin Transplant; 1997 Dec; 11(6):613-7. PubMed ID: 9408695
[TBL] [Abstract][Full Text] [Related]
4. Cytomegalovirus UL97 mutations associated with ganciclovir resistance in immunocompromised patients from Argentina.
Sánchez Puch S; Ochoa C; Carballal G; Zala C; Cahn P; Brunet R; Salomón H; Videla C
J Clin Virol; 2004 Jul; 30(3):271-5. PubMed ID: 15135748
[TBL] [Abstract][Full Text] [Related]
5. Preemptive use of oral ganciclovir to prevent cytomegalovirus infection in liver transplant patients: a randomized, placebo-controlled trial.
Paya CV; Wilson JA; Espy MJ; Sia IG; DeBernardi MJ; Smith TF; Patel R; Jenkins G; Harmsen WS; Vanness DJ; Wiesner RH
J Infect Dis; 2002 Apr; 185(7):854-60. PubMed ID: 11920308
[TBL] [Abstract][Full Text] [Related]
6. Cytomegalovirus (CMV) resistance in patients with CMV retinitis and AIDS treated with oral or intravenous ganciclovir.
Drew WL; Stempien MJ; Andrews J; Shadman A; Tan SJ; Miner R; Buhles W
J Infect Dis; 1999 Jun; 179(6):1352-5. PubMed ID: 10228054
[TBL] [Abstract][Full Text] [Related]
7. [Advances in the diagnosis and treatment of infections caused by herpesvirus and JC virus].
Arribas JR; Arrizabalaga J; Mallolas J; López-Cortés LF
Enferm Infecc Microbiol Clin; 1998; 16 Suppl 1():11-9. PubMed ID: 9859615
[TBL] [Abstract][Full Text] [Related]
8. Ganciclovir implants: one year later.
Cadman J
GMHC Treat Issues; 1997; 11(4/5):3-6. PubMed ID: 11364375
[TBL] [Abstract][Full Text] [Related]
9. Randomized controlled trial of oral ganciclovir versus oral acyclovir after induction with intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in cytomegalovirus-seropositive liver transplant recipients.
Winston DJ; Busuttil RW
Transplantation; 2003 Jan; 75(2):229-33. PubMed ID: 12548129
[TBL] [Abstract][Full Text] [Related]
10. Emergence and persistence of multiple antiviral-resistant CMV strains in a highly immunocompromised child.
Iwasenko JM; Scott GM; Ziegler JB; Rawlinson WD
J Clin Virol; 2007 Oct; 40(2):152-5. PubMed ID: 17698411
[TBL] [Abstract][Full Text] [Related]
11. Once daily ganciclovir as initial pre-emptive therapy delayed until threshold CMV load > or =10000 copies/ml: a safe and effective strategy for allogeneic stem cell transplant patients.
Verkruyse LA; Storch GA; Devine SM; Dipersio JF; Vij R
Bone Marrow Transplant; 2006 Jan; 37(1):51-6. PubMed ID: 16284613
[TBL] [Abstract][Full Text] [Related]
12. Oral ganciclovir.
Schouten JT
STEP Perspect; 1995; 7(3):1, 11. PubMed ID: 11362979
[TBL] [Abstract][Full Text] [Related]
13. Ganciclovir prophylaxis for CMV disease infrequently associated with viral resistance.
AIDS Patient Care; 1995 Dec; 9(6):308. PubMed ID: 11361450
[No Abstract] [Full Text] [Related]
14. A pilot phase II study of alternate day ganciclovir and foscarnet in preventing cytomegalovirus (CMV) infections in at-risk pediatric and adolescent allogeneic stem cell transplant recipients.
Shereck EB; Cooney E; van de Ven C; Della-Lotta P; Cairo MS
Pediatr Blood Cancer; 2007 Sep; 49(3):306-12. PubMed ID: 16972242
[TBL] [Abstract][Full Text] [Related]
15. A comparative randomised study of valacyclovir vs. oral ganciclovir for cytomegalovirus prophylaxis in renal transplant recipients.
Pavlopoulou ID; Syriopoulou VP; Chelioti H; Daikos GL; Stamatiades D; Kostakis A; Boletis JN
Clin Microbiol Infect; 2005 Sep; 11(9):736-43. PubMed ID: 16104989
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of ganciclovir in pediatric renal transplant recipients.
Zhang D; Lapeyraque AL; Popon M; Loirat C; Jacqz-Aigrain E
Pediatr Nephrol; 2003 Sep; 18(9):943-8. PubMed ID: 12883977
[TBL] [Abstract][Full Text] [Related]
17. Treatment of cytomegalovirus (CMV) retinitis with intravitreous ganciclovir in HIV-infected children.
Surachatkumtonekul T; Chokephaibulkit K; Vanprapar N; Pamonvaechavan P
J Med Assoc Thai; 2008 Mar; 91(3):331-7. PubMed ID: 18575285
[TBL] [Abstract][Full Text] [Related]
18. Emergence of drug-resistant cytomegalovirus retinitis in the contralateral eyes of patients with AIDS treated with ganciclovir.
Imai Y; Shum C; Martin DF; Kuppermann BD; Drew WL; Margolis TP
J Infect Dis; 2004 Feb; 189(4):611-5. PubMed ID: 14767813
[TBL] [Abstract][Full Text] [Related]
19. Intravitreal toxicology and duration of efficacy of a novel antiviral lipid prodrug of ganciclovir in liposome formulation.
Cheng L; Hostetler KY; Chaidhawangul S; Gardner MF; Beadle JR; Keefe KS; Bergeron-Lynn G; Severson GM; Soules KA; Mueller AJ; Freeman WR
Invest Ophthalmol Vis Sci; 2000 May; 41(6):1523-32. PubMed ID: 10798672
[TBL] [Abstract][Full Text] [Related]
20. A randomized prospective controlled trial of oral ganciclovir versus oral valacyclovir for prophylaxis of cytomegalovirus disease after renal transplantation.
Reischig T; Opatrny K; Bouda M; Treska V; Jindra P; Svecova M
Transpl Int; 2002 Dec; 15(12):615-22. PubMed ID: 12478408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
